Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
ConditionHepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorGuangxi Medical University
About this trial
This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically or clinically confirmed diagnosis of HCC.
Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy.
Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1.
With Child-Pugh 5~7 scores.
Disqualifiers
Concurrent with other malignancies within 5 years.
Incomplete medical data.
Follow-up time less than 3 months.
Trial population
Patients with hepatocellular carcinoma who received conversion or neoadjuvant therapy as initial treatment would be included.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Conversion or neoadjuvant therapy.
DrugPatients with hepatocellular carcinoma received conversion or neoadjuvant therapy.
Treatment groups
2,000 Participants
are divided into 1 treatment groupGroup A: Conversion or Neoadjuvant Therapy1 intervention
Trial outcomes
Primary outcomes
1
Overall survival
1 year overall survival
Time frame
1 yearSecondary outcomes
1
progression-free survival
1 year progression-free survival
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov